🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07012486
Recruiting Phase EARLY_PHASE1

Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

NCT07012486 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Zhongshan Hospital
Phase
Phase EARLY_PHASE1
Started
2025-06
Last updated
2025-06-10

Condition(s) studied

Androgenetic Alopecia (AGA)

Investigational drug(s) / intervention(s)

Oral DHA + Topical minoxidil 5%Topical Minoxidil 5%

Oral DHA + Topical minoxidil 5%: DHA 20mg tid po plus daily topical minoxidil 5% for 180 days

Topical Minoxidil 5%: Topical minoxidil 5% daily for 180 days

Study summary

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is:

• Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA.

Participants will:

* Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months.
* Visit the clinic once every month for checkups and tests.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Clinically diagnosed with androgenetic alopecia (AGA) * No pregnancy plans within the next 6 months Exclusion Criteria: * Patients who received systemic medications for hair loss within the past 2 months * Use of topical medication for hair loss within the past 2 weeks * Pregnancy or lactation * Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zhongshan Hospital Fudan University Shanghai Shanghai Municipality Recruiting

More Shanghai Zhongshan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07012486 on ClinicalTrials.gov ↗ ← All trials in China